Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma

D. Azambuja, Y. Natkunam, I. Biasoli, I. S. Lossos, M. W. Anderson, J. C. Morais, N. Spector

Research output: Contribution to journalArticle

65 Scopus citations


Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). Patients and methods: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. Results: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. Conclusion: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.

Original languageEnglish (US)
Pages (from-to)736-742
Number of pages7
JournalAnnals of Oncology
Issue number3
StatePublished - Mar 1 2012



  • CD68
  • Hodgkin's lymphoma
  • Macrophages
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this